Evidence map›Paper›PMID 42804021›Full record

ArticleBreast cancer research and treatment2026

Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force "Dermatology for Cancer Patients" and pharmacovigilance analysis.

Ioannis-Alexios Koumprentziotis, Alexander Cawley, Elliot Ewig, Alexandre O Gérard, Maëlys Labat, Grażyna Kamińska-Winciorek, Marcin Kubeczko, Luca Rapparini, Michela Starace, Katerina Grafanaki and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ioannis-Alexios KoumprentziotisFirst Dermatology Department, "A.Sygros" Hospital for Skin Diseases, National and Kapodistrian University of Athens Medical School, Athens, Greece. giannhskmpr@gmail.com.ORCID https://orcid.org/0000-0002-1156-7139
Alexander CawleyDermatology Department, Skin Unit, Royal Marsden NHS Foundation Trust, London, UK.
Elliot EwigDepartment of Clinical Pharmacology, Université Côte d'Azur, University Hospital Centre of Nice, Nice, France.
Alexandre O GérardDepartment of Clinical Pharmacology, Université Côte d'Azur, University Hospital Centre of Nice, Nice, France.
Maëlys LabatSaint Louis Régional Pharmacovigilance Centre, Clinical Investigation Centre (INSERM CIC 1427), Saint-Louis Hospital, Paris, 75010, France.
Grażyna Kamińska-WinciorekMaria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Marcin KubeczkoMaria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Luca RappariniDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Michela StaraceDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Katerina GrafanakiDepartment of Dermatology-Venereology, School of Medicine, University of Patras, Patras, Greece.
Maria KamaratouDepartment of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece.
Dimitrios MavroudisDepartment of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece.
Alexander Katoulis2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece.
Vasiliki NikolaouFirst Dermatology Department, "A.Sygros" Hospital for Skin Diseases, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Kara HeelanDermatology Department, Skin Unit, Royal Marsden NHS Foundation Trust, London, UK.
Dimitra Koumaki2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSacituzumab govitecan (SG) is an antibody-drug conjugate approved across multiple metastatic breast cancer settings. Although hematologic and gastrointestinal toxicities dominate its safety profile, dermatologic adverse events (dAEs) remain poorly characterized, despite the physiological expression of Trop-2 in epidermal keratinocytes. We aimed to comprehensively characterize the spectrum, severity, time to onset, and oncologic impact of SG-associated dAEs across real-world and pharmacovigilance data sources.

methodsAn international retrospective cohort study was conducted within the EADV Task Force "Dermatology for Cancer Patients" (n = 56 breast cancer patients). Findings were triangulated with disproportionality analyses of the WHO Global Pharmacovigilance database (VigiBase

resultsAcross all data sources, alopecia was the most frequently reported dAE (EADV cohort: 41.1%; FPVD: 52.2%; VigiBase

conclusionSG-associated dAEs are predominantly low-grade and infrequently precipitate treatment discontinuation. Pharmacovigilance data raises a potential signal for cutaneous infections that warrants further investigation. As SG increasingly enters combination regimens, structured dermatologic monitoring and prospective characterization of dAEs are essential to guide oncodermatologic management and protect oncological outcomes. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Antibodies, Monoclonal, HumanizedBreast NeoplasmsCamptothecinDrug EruptionsImmunoconjugatesAdultAgedAlopeciaFemaleHumansMiddle AgedPharmacovigilanceRetrospective StudiesAntibodies, Monoclonal, HumanizedCamptothecinImmunoconjugatessacituzumab govitecanAntibody–drug conjugateBreast cancerDermatologic adverse eventsOncodermatologyPharmacovigilanceSacituzumab govitecan

Identifiers

PMID42804021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.